ABVC Biopharma Files 8-K/A Amendment
Ticker: ABVC · Form: 8-K/A · Filed: Jun 24, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $3,500,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-definitive-agreement, filing
TL;DR
ABVC Bio amended its 8-K filing from March, no new info but procedural update.
AI Summary
ABVC Biopharma, Inc. filed an amendment (8-K/A) on June 24, 2024, to a previous Form 8-K dated March 26, 2024. This amendment pertains to the entry into a material definitive agreement and includes financial statements and exhibits. The filing does not provide new details on the agreement itself but serves as an update to the original report.
Why It Matters
This filing is an amendment to a previous report, indicating a procedural update rather than new material information about a definitive agreement or financial performance.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material events or financial information.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- 0001213900-24-055288 (filing_id) — Accession Number
- 20240624 (date) — Filing Date
- 20240326 (date) — Earliest Event Reported Date
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previously filed Form 8-K, specifically addressing the entry into a material definitive agreement and including financial statements and exhibits.
When was the original Form 8-K filed, and what was the earliest event reported?
The original Form 8-K was filed on March 26, 2024, and that date is also the earliest event reported.
What is the filing date of this amendment?
The filing date of this amendment (8-K/A) is June 24, 2024.
What is the company's state of incorporation and IRS Employer Identification Number?
ABVC Biopharma, Inc. is incorporated in Nevada and its IRS Employer Identification Number is 26-0014658.
Does this amendment provide new details about the material definitive agreement?
The filing itself does not explicitly state new details about the agreement; it is an amendment to a previous report concerning the entry into such an agreement and related financial statements/exhibits.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2024-06-24 17:15:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
- $3,500,000 — cond milestone payment in the amount of $3,500,000 per Licensing Agreement, incrementally
- $100,000 — nsing Agreement, incrementally (such as $100,000), at any given time, rather than in one
Filing Documents
- ea0208383-8ka1_abvcbio.htm (8-K/A) — 27KB
- ea020838301ex10-1_abvcbio.htm (EX-10.1) — 10KB
- ea020838301ex10-2_abvcbio.htm (EX-10.2) — 10KB
- 0001213900-24-055288.txt ( ) — 223KB
- abvc-20240326.xsd (EX-101.SCH) — 3KB
- abvc-20240326_lab.xml (EX-101.LAB) — 33KB
- abvc-20240326_pre.xml (EX-101.PRE) — 22KB
- ea0208383-8ka1_abvcbio_htm.xml (XML) — 4KB
01 Entry into Material Definitive Agreements
Item 1.01 Entry into Material Definitive Agreements On March 25, 2024, ABVC BioPharma, Inc. (the " Company "), and one of its co-development partners, BIOFIRST CORPORATION, a company registered in Taiwan (" BIOFIRST "), filed the initial Current Report on Form 8-K to disclose that it entered into a definitive agreement with ForSeeCon Eye Corporation, a private company registered in the British Virgin Islands (" FEYE "), pursuant to which the Company and BIOFIRST entered into a twenty-year, global definitive licensing agreement (the " Licensing Agreement ") for the products in the Company and BIOFIRST's Ophthalmology pipeline, including Vitargus (the " Licensed Products "). On June 18, 2024, the Company and BIOFIRST, each entered into an amendment (the " Amendment ") to the Licensing Agreement with FEYE, pursuant to which the Company and BIOFIRST have agreed to allow FEYE to pay the second milestone payment in the amount of $3,500,000 per Licensing Agreement, incrementally (such as $100,000), at any given time, rather than in one lump sum. The foregoing descriptions of the agreements are not complete and are qualified in their entirety by reference to the full text of the agreements, copies of which are attached as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K/A and incorporated herein by reference.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits (d) Exhibits Exhibit No. Description 10.1 Amendment to the Definitive License Agreement between the Company and ForSeeCon Eye Corporation 10.2 Amendment to the Definitive License Agreement between BIOFIRST CORPORATION and ForSeeCon Eye Corporation 10.3 Definitive License Agreement between the Company and ForSeeCon Eye Corporation (incorporated by reference to Exhibit 10.1 of the 8K filed on March 26, 2024) 10.4 Definitive License Agreement between BIOFIRST CORPORATION and ForSeeCon Eye Corporation (incorporated by reference to Exhibit 10.2 of the 8K filed on March 26, 2024) 104 Cover Page Interactive Data File, formatted in Inline XBRL 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. June 24, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2